Morgan Stanley has reported a significant reduction in its ownership stake in Axogen, Inc. According to a recent filing, the financial services giant now holds 2.8% of the common stock of Axogen, down from a previous higher percentage. This change is noteworthy as it marks Morgan Stanley's exit from being a beneficial owner of more than five percent of Axogen's shares.

The filing, made on November 13, 2026, indicates that Morgan Stanley's current beneficial ownership includes shared voting power over 1,551,105 shares and shared dispositive power over 1,662,486 shares of Axogen. The updated ownership structure may reflect strategic adjustments within Morgan Stanley's investment portfolio.

Background

Morgan Stanley, incorporated in Delaware, is a major player in the financial services industry, classified under SIC code 6211, which encompasses security brokers, dealers, and flotation companies. The firm operates on the New York Stock Exchange and is recognized as a large accelerated filer. Its recent filings include multiple Schedule 13G and Schedule 13G/A forms, indicating ongoing adjustments in its investment strategies.

What the Filing Says

The Schedule 13G/A filing states, "As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities." This highlights a notable shift in their investment approach concerning Axogen, Inc.

Impact

This reduction in stake may affect various stakeholders, including investors and analysts monitoring Axogen's performance. The change could signal a reevaluation of Axogen's market position and future growth potential, prompting other investors to reassess their holdings in the company.

What's Next

The filing does not say what happens next.